SCHEMBL1699089

SCHEMBL1699089

CC(C)(C)[Si](C)(C)OC=O

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL828323 0.73 TDP1 (0.38) TDP1
SCHEMBL2347832 0.73
SCHEMBL894183 0.71
SCHEMBL16938679 0.69
SCHEMBL7893172 0.67 TDP1 (0.30) TDP1
SCHEMBL6853 0.67
SCHEMBL7895519 0.67
SCHEMBL2224330 0.67
SCHEMBL21522943 0.67
SCHEMBL17150227 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4837349-A Tertiary-butyldimethylsilyl carbamate derivative and process for producing the same SUNTORY LIMITED (JP) 1989-06-06 US claimed
EP-0217243-A2 Tertiary-butyldimethylsilyl carbamate derivative and process for producing the same SUNTORY LIMITED (JP) 1987-04-08 EP claimed
CN-115276929-A Transmission method, device and system 华为技术有限公司 2022-11-01 CN disclosed
US-9567354-B2 Amino acid-modified silane compounds and making method SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-02-14 US disclosed
CN-104540844-B C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity 百时美施贵宝公司 2016-12-07 CN disclosed
EP-2687529-B1 CONDENSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-07-13 EP disclosed
US-9226921-B2 Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-05 US disclosed
US-9029388-B2 Condensed heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-12 US disclosed
US-8940758-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-27 US disclosed
US-8846713-B2 Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-09-30 US disclosed
US-20140228320-A1 FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-14 US disclosed
US-4937331-A Chemical intermediates for antibiotics PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1990-06-26 US disclosed
EP-0334593-A1 Chiral azetidinone epoxides THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1989-09-27 EP disclosed
US-4855420-A Cephalosporin derivatives ICI PHARMA (FR) 1989-08-08 US disclosed
US-4837349-A Tertiary-butyldimethylsilyl carbamate derivative and process for producing the same SUNTORY LIMITED (JP) 1989-06-06 US disclosed
US-4837349-A Tertiary-butyldimethylsilyl carbamate derivative and process for producing the same SUNTORY LIMITED (JP) 1989-06-06 US disclosed
US-4678781-A BACTERICIDAL ANTIBIOTICS ICI PHARMA (FR) 1987-07-07 US disclosed
EP-0217243-A2 Tertiary-butyldimethylsilyl carbamate derivative and process for producing the same SUNTORY LIMITED (JP) 1987-04-08 EP disclosed
EP-0217243-A2 Tertiary-butyldimethylsilyl carbamate derivative and process for producing the same SUNTORY LIMITED (JP) 1987-04-08 EP disclosed
EP-0127992-A2 Cephalosporin derivatives ICI PHARMA (FR) 1984-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228320-A1 FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS PDE3A, PDE5A, PDE2A TDP1 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.